William Blair analyst Brandon Vazquez has maintained their bullish stance on ZTS stock, giving a Buy rating on October 10.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brandon Vazquez has given his Buy rating due to a combination of factors, including the company’s strategic initiatives and market positioning. Despite some short-term challenges, such as a slight decline in distributor levels for the U.S. Companion Animal business, Vazquez remains optimistic about Zoetis’s long-term growth potential.
He acknowledges that while there may be some immediate risks due to distributor noise and competitive pressures, the introduction of new products by 2026 is expected to drive share value upwards. Vazquez’s confidence is further supported by the company’s valuation, which he believes is attractive at 21 times the estimated earnings per share for 2026.
Vazquez covers the Healthcare sector, focusing on stocks such as Neogen, PROCEPT BioRobotics, and Align Tech. According to TipRanks, Vazquez has an average return of -3.3% and a 31.75% success rate on recommended stocks.
In another report released on October 10, Bank of America Securities also maintained a Buy rating on the stock with a $200.00 price target.